INVO Bioscience Operating Income

INVO Bioscience (INVO) currently reports a operating income of $10B as of June 2026. That compares with $-28B in the prior-year period — up 135.4% year over year. Use the charts on this page to explore INVO Bioscience's operating income history and peer comparisons.

INVO Bioscience's operating income increased from $-28B to $10B — a 135.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

INVO Bioscience reported $10B in operating income as of June 2026. That compares with $-28B in the prior-year period — up 135.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $10B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for INVO Bioscience, and consider following INVO for alerts when major investors trade the stock.

INVO Bioscience is classified in the Healthcare sector. On operating income, it currently shows $10B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INVO with unrelated industries.